American Research & Management Company’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $977K | Sell |
3,658
-335
| -8% | -$71.1K | 0.27% | 66 |
|
|
2022
Q2 | $814K | Sell |
3,993
-596
| -13% | -$122K | 0.21% | 75 |
|
|
2022
Q1 | $966K | Sell |
4,589
-355
| -7% | -$77.2K | 0.21% | 72 |
|
|
2021
Q4 | $1.19M | Sell |
4,944
-1,095
| -18% | -$282K | 0.26% | 66 |
|
|
2021
Q3 | $1.71M | Sell |
6,039
-410
| -6% | -$134K | 0.39% | 58 |
|
|
2021
Q2 | $2.23M | Sell |
6,449
-202
| -3% | -$61.2K | 0.51% | 52 |
|
|
2021
Q1 | $1.86M | Sell |
6,651
-140
| -2% | -$37.8K | 0.45% | 55 |
|
|
2020
Q4 | $1.66M | Sell |
6,791
-100
| -1% | -$25.8K | 0.43% | 55 |
|
|
2020
Q3 | $1.96M | Sell |
6,891
-39
| -0.6% | -$10.9K | 0.57% | 49 |
|
|
2020
Q2 | $1.85M | Hold |
6,930
| – | – | 0.56% | 48 |
|
|
2020
Q1 | $2.19M | Sell |
6,930
-100
| -1% | -$30.3K | 0.83% | 39 |
|
|
2019
Q4 | $2.09M | Sell |
7,030
-1,725
| -20% | -$479K | 0.62% | 47 |
|
|
2019
Q3 | $2.04M | Sell |
8,755
-1,315
| -13% | -$306K | 0.61% | 45 |
|
|
2019
Q2 | $2.35M | Sell |
10,070
-320
| -3% | -$73.9K | 0.7% | 40 |
|
|
2019
Q1 | $2.46M | Hold |
10,390
| – | – | 0.7% | 38 |
|
|
2018
Q4 | $3.13M | Sell |
10,390
-25
| -0.2% | -$7.98K | 1.05% | 30 |
|
|
2018
Q3 | $3.68M | Buy |
10,415
+60
| +0.6% | +$20.7K | 1.09% | 28 |
|
|
2018
Q2 | $3M | Buy |
10,355
+1,145
| +12% | +$322K | 1.04% | 29 |
|
|
2018
Q1 | $2.52M | Buy |
9,210
+110
| +1% | +$34.1K | 0.83% | 35 |
|
|
2017
Q4 | $2.9M | Buy |
9,100
+65
| +0.7% | +$20.9K | 0.89% | 34 |
|
|
2017
Q3 | $2.83M | Buy |
9,035
+85
| +0.9% | +$25.2K | 0.92% | 35 |
|
|
2017
Q2 | $2.43M | Buy |
8,950
+125
| +1% | +$33.1K | 0.8% | 39 |
|
|
2017
Q1 | $2.41M | Buy |
8,825
+950
| +12% | +$269K | 0.86% | 36 |
|
|
2016
Q4 | $2.23M | Sell |
7,875
-40
| -0.5% | -$11.9K | 0.76% | 39 |
|
|
2016
Q3 | $2.48M | Buy |
7,915
+1,100
| +16% | +$326K | 0.9% | 35 |
|
|
2016
Q2 | $1.65M | Buy |
6,815
+1,890
| +38% | +$498K | 0.63% | 48 |
|
|
2016
Q1 | $1.28M | Buy |
4,925
+680
| +16% | +$180K | 0.54% | 52 |
|
|
2015
Q4 | $1.3M | Buy |
4,245
+1,985
| +88% | +$570K | 0.56% | 52 |
|
|
2015
Q3 | $659K | Buy |
2,260
+1,990
| +737% | +$657K | 0.29% | 73 |
|
|
2015
Q2 | $109K | Hold |
270
| – | – | 0.04% | 131 |
|
|
2015
Q1 | $114K | Sell |
270
-30
| -10% | -$11.8K | 0.05% | 126 |
|
|
2014
Q4 | $102K | Hold |
300
| – | – | 0.04% | 130 |
|
|
2014
Q3 | $99K | Hold |
300
| – | – | 0.04% | 140 |
|
|
2014
Q2 | $95K | Hold |
300
| – | – | 0.03% | 141 |
|
|
2014
Q1 | $92K | Hold |
300
| – | – | 0.03% | 137 |
|
|
2013
Q4 | $84K | Hold |
300
| – | – | 0.03% | 144 |
|
|
2013
Q3 | $72K | Hold |
300
| – | – | 0.03% | 147 |
|
|
2013
Q2 | $65K | Buy |
+300
| New | +$64.1K | 0.03% | 154 |
|
Other funds holding BIIB
American Research & Management Company's BIIB Position: Q3 2022 in Review
American Research & Management Company reduced its Biogen (BIIB) stake by 8.4% in Q3 2022, selling an estimated $71.1K and leaving 3,658 shares worth $977K. The position accounts for 0.27% of the portfolio, ranked #66.
American Research & Management Company first reported a position in BIIB in Q2 2013 and has held it in 38 quarters since. The position peaked at $3.68M in Q3 2018. 987 funds tracked by Wall St. Rank hold BIIB as of Q3 2022.
- American Research & Management Company held 3,658 shares of Biogen worth $977K as of Q3 2022.
- American Research & Management Company sold 335 Biogen shares in Q3 2022, an estimated $71.1K.
- Biogen made up 0.27% of American Research & Management Company's portfolio in Q3 2022, its #66 holding.
- American Research & Management Company first reported a position in Biogen in Q2 2013 and has held it in 38 quarters since.
- American Research & Management Company's Biogen position peaked at $3.68M in Q3 2018.
- 987 funds tracked by Wall St. Rank held Biogen as of Q3 2022.
Based on American Research & Management Company's 13F filing for Q3 2022, filed 7 Oct 2022.